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Abstract
Neurogenesis in adults, initiated by injury to the central nervous system (CNS) presents an autologous repair
mechanism. It has been suggested that hyperbaric oxygen therapy (HBOT) enhances neurogenesis which
accordingly may improve functional outcome after CNS injury. In this present article we aim to review
experimental as well as clinical studies on the subject of HBOT and neurogenesis. We demonstrate hypothetical
mechanism of HBOT on cellular transcription factors including hypoxia-inducible factors (HIFs) and cAMP response
element binding (CREB). We furthermore reveal the discrepancy between experimental findings and clinical trials in
regards of HBOT. Further translational preclinical studies followed by improved clinical trials are needed to
elucidate potential benefits of HBOT.
Introduction
Neurogenesis is defined as generation of neurons within
the brain. In adults, neurogenesis occurs primarily in two
brain regions: the subventricular (SVZ) and the subgranu-
l a rz o n e( S G Z )o ft h eh i p p o c a m p a ld e n t a t eg y r u s( D G ) .
Injury to the central nervous system (CNS) including
trauma, cerebral ischemia and epileptic seizures have been
reported to induce neurogenesis, and surviving cells may
be functionally integrated into existing neural circuits [1].
Consequently, further endogenous promotion of neuro-
genesis may hold promise for restoration of cerebral func-
tions after CNS injury.
Hyperbaric oxygen therapy (HBOT) refers to the medi-
cal use of oxygen at a level higher than atmospheric pres-
sure. Initially, indicated for decompression illness it has
been further applied to clinical conditions including
crush injury, diabetic foot, skin grafts, thermal burns and
to several neurological diseases [2]. Elevation of partial
oxygen pressure in the body, leads to increased oxygen
transport capacity of erythrocytes, facilitating peripheral
regeneration processes (e.g. angiogenesis).
It has been suggested that HBOT exerts neuroprotec-
tive effects through a variety of mechanisms, including
the activation of cellular transcription factors [3]. How-
ever, due to inconsistent results and few clinical trials,
HBOT for neurologic disorders has not yet been
approved by the FDA. Further preclinical studies are
needed to clarify the effect of HBOT on neurogenesis
and to ensure a successful translation to clinical trials.
Literature Review
Publications were identified by PubMed/Medline and
Web of Science, using the following keywords: neurogen-
esis, hyperbaric oxygen, ischemia, proliferation and BrdU.
All publications, languages and subsets were explored.
Results from previous studies were summarized into the
following four categories: hypoxic-ischemic encephalopa-
thy (HIE) (Table 1), vascular dementia (Table 2), perma-
nent middle cerebral artery occlusion (MCAo) (Table 3)
and human mesencephalic neural progenitor cells
(hmNPCs) (Table 4).
Regarding HBOT, most preclinical studies were per-
formed using a rat model of HIE. Wang et al. initiated 7
days of HBOT (2.0 ATA, 100% oxygen, 1 hour daily) start-
ing 3 hours after experimental HIE in rats. Results showed
a significantly increased amount of BrdU+/nestin+ cells in
the SVZ with a peak at 7 days after HIE [4]. 21 days later,
more BrdU+/b-tubulin+ cells were observed in the cortex
of treated rats, suggesting that HBOT promotes the prolif-
eration, differentiation and migration of newly generated
cells [5].
Our preliminary data shows that HBOT decreases the
infarct size with a significantly increased number of BrdU
(+) cells in the peri-infarct area 2 week after experimental
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Animal model/
Cell line
HBO therapy Method/Duration Neurogenesis Infarct
size
Neurobehavioral
testing
Mechanism Institute Reference
HIE rats Within 3 h 100%, 2 ATA
1 h/d × 7
BrdU 50 mg/Kg 2 days
before sac Q8hX5T
SVZ ↑Brdu+/nestin+ D3, D7, D14 after ischemia / / Wnt-3 Central South
University, China
Wang, et
al [4]
HIE rats Within 3 h 100%, 2 ATA
1 h/d × 7
brdU 50 mg/Kg 1 days
after surgery Q12hX6D
SVZ ↑Brdu+/nestin+ D3, D7, D14 after ischemia / / MBP Central South
University, China
Yang, et al
[11]
HIE rats Within 3 h 2 ATA, 100%
oxygen 1 h/d × 7
brdU 50 mg/Kg 1 days
before HBO Q12hX6D
↑D7 SVZ brdu+/DCX+ ↑D14 cortex brdu+/DCX
+ D28 cortex ↑BrdU/GFAP/tubulin
/ / / Central South
University, China
Wang, et
al [5]
neural stem cell
from HIE rats
Within 2 h 2 ATA, 100%
oxygen × 1 h
/ differentiate into ↑neurons ↑oligodendrocytes
↓astrocytes
// b-catenin, Central South
University, China
Zhang, et
al [6]
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7HIE. We treated operated animals with 1.5 ATA HBO,
100% oxygen once a day for 3 consecutive days. BrdU,
dissolved in saline, was injected intraperitoneally (50 mg/
kg) 24 hours after HIE, once a day for a total of 7 days.
Furthermore in vitro studies suggest that HBOT pro-
motes neural stem cells differentiation into neurons or
oligodendrocytes, while inhibiting those stem cells from
differentiating into astrocytes [6,7]. HBOT also enhances
the proliferation of other supporting cells, including glial
cell line-derived neurotrophic nerve growth factor
(GDNF) [8] and vascular endothelial growth factor
(VEGF) positive cells [8] as well as epithelial cells [9]
and human microvascular endothelial cells (HMEC-1)
(Table 5) [10].
Hypothetical mechanisms
Numerous in vivo and in vitro studies confirm that
HBOT induces neurogenesis [5-7,10-13] however, under-
lying mechanisms remain unknown. Activation of several
signaling pathways and transcription factors have been
suggested to play an important role in HBOT induced
neurogenesis, including Wnt, hypoxia-inducible factors
(HIFs) and cAMP response element-binding (CREB).
HIF-1 is a heterodimeric transcriptional complex com-
posed of an inducible HIF-1a subunit and a constitutive
HIF-1b subunit. HIF-1a is the principal mediator of cel-
lular hypoxia adaptations [14]. Therefore activated by
hypoxia, HIF-1a causes the transcription of its regulated
downstream genes, including erythropoietin (EPO) and
VEGF which are known to promote neurogenesis [15].
However accumulation of HIF-1a induces expression of
p53 [16] and BNIP3 [17], leading to neuronal cell death.
Thus neuroprotection may occur shortly after cerebral
ischemia at balanced levels of HIF-1a. In the presence of
oxygen and iron, HIF-1a is rapidly degraded via the pro-
lyl hydroxylase pathway. Javorina et al. discovered that
HBOT exposure stabilizes HIF-1a levels in hmNPCs and
furthermore induces neurogenesis in vitro [7]. We sug-
gest that HBOT prevents the accumulation of HIF-1a
and therefore exerts its neuroprotective effect (Figure 1).
Wnt signaling has been suggested to play an impor-
tant role in the regulation of cell proliferation and dif-
ferentiation during the stage of CNS development. Wnt-
3 is the starting protein of this pathway. Wang et al.
confirmed increased level of Wnt-3 in HBOT rats 3
days after HIE induction, which was positively correlated
with the proliferation of stem cells [4]. The authors sug-
gest that cell proliferation via Wnt pathway is regulated
through b-catenin. Furthermore, in vitro studies demon-
strated that b-catenin siRNA decreases the amount of
newly generated neurons by repressing the Neurogenin1
(NGN1) gene, which can be reversed by HBOT [6]. It
has been recently reported that HIF-1a modulates Wnt/
b-catenin signaling in hypoxic embryonic stem cells
(ESC) by enhancing b-catenin activation, and expression
of the downstream effectors lymphocyte enhancer fac-
tor-1 (LEF-1) and T-cell factor-1 (TCF-1) [18].
It has been implicated that Hif-1a deletion reduces
Wnt/b-catenin signaling in the SGZ, causing impaired
Wnt-dependent processes, including neural stem cell pro-
liferation, differentiation and neuronal maturation [18].
We conclude that activation of the Wnt pathway may
occur via HBOT induced control of HIF-1a (Figure 1).
CREB plays a well-documented role in neuronal plasti-
city and formation of long-term memory, mainly through
up-regulation of its downstream genes including brain
derived neurophic factor (BDNF), Bcl-2, c-fos and VGF.
Activation of CREB increases neurogenesis in the DG
after focal cerebral ischemia in rats, and protects against
hypoxic brain injury [19]. Application of 100% oxygen
increased CREB expression in striatum and hippocampus
in a neonatal piglet model of intermittent apnea [20].
HBO preconditioning furthermore increased the ratio of
Bcl-2 and Bax expression in a MCAo/reperfusion model
Table 2 Vascular dementia
Animal model/
Cell line
HBO therapy Method/
Duration
Neurogenesis Infarct
size
Neurobehavioral
testing
Mechanism Institute Reference
vascular dementia
(ligation of
Bilateral CCA)
100%,2 ATA,
2 h/d × 10d
/ piriform cortex
(Pir)
↑DCX+, Nestin
+
/ Shuttle box
testing
/ Third
Military Medical
University
Zhang et al
[12]
Table 3 Permanent MCAo
Animal
model/Cell
line
HBO therapy Method/
Duration
Neurogenesis Infarct
size
Neurobehavioral
testing
Mechanism Institute Reference
Permanent
MCAo
100%,2.5 ATA,
1.5 h
From 15 min, 1.5 h, 3
h after MCAo
/D 7
↑GFAP+
↓ garcia / University of
Leipzig, Germany
Gunther,
et al [13]
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Page 3 of 7[21]. CREB activates its downstream genes when phos-
phorylated, while protein phosphatase-1 (PP1) catalyzes
the dephosphorylation of CREB. PP1g modulates the
localization and/or activity of PP1. Suppressed in hypoxic
conditions, PP1 leads to over-phosphorylation of CREB,
followed by CREB ubiquitination and degradation by 26s
proteasome [22]. Although the exact role of CREB in
HBOT induced neurogenesis is still not clear, we sug-
gested that HBOT could reverse this process by reactivat-
ing PP1g and by blocking the degradation of CREB
(Figure 2).
Clinical applications
Stroke
Neurons are highly energy demanding, a characteristic
which makes them vulnerable to decreased cerebral
blood supply during stroke. Experimental transient
ischemia induces neurogenesis in the DG, with a peak
between 7-10 days [23]. In confirmation to these results
Shin et al. found the highest number of Brdu+ cells in
the SVZ, subependymal zone, cortex and striatum 1
week after MCAo [24]. Thus endogenous neurogenesis
after ischemic stroke occurs early and is short-lived.
HBOT appears to be a potent method of oxygen deliv-
ery [25]. It increases the oxygen partial pressure within
the blood and enhances restoration of oxygen supply
after ischemic stroke [26]. Previous studies provide evi-
dence that HBOT promotes neurogenesis [4-6,11],
reduces infarct size [27,28] as well as hemorrhagic trans-
formation [29] and improves neurological function, in
animal models of ischemic stroke [28].
In contrast to these preclinical results no benefit of
HBOT was found in stroke patients [30] and HBOT did
not improve the clinical outcome in patients 6 months
after acute stroke [31]. However, Singhal concluded that
HBOT might extend the time window and increase the
efficiency of FDA approved r-tPA thrombolysis after
acute ischemic stroke [25].
Most clinical trials presented small sample sizes,
undifferentiated stroke types, diverse time windows and
varying application of HBOT. To bridge the gap
between basic science and clinical studies, large scale,
well designed, randomized controlled clinical trials are
needed to examine the effects on HBOT in terms of
acute sensorimotor and chronic cognitive function in
patients.
Traumatic brain injury (TBI)
It has been established that injury-induced neurogenesis
contributes greatly to post-injury recovery. After TBI,
hippocampal progenitors are activated and result in
increased amount of newly generated neurons within
the DG [32]. Although there is no literature available on
the HBOT induced neurogenesis in preclinical TBI
models, HBOT has been applied to TBI patients. The
use of HBOT for TBI remains controversial. McDonagh
et al., concluded that there was insufficient evidence to
establish the effectiveness of HBOT in the treatment of
TBI [33]. Rockswold et al., on the other hand, found
that HBOT might be potentially beneficial for severe
TBI patients [34]. The safety of HBOT was also evalu-
ated and it was pointed out that, if given at proper
Table 4 Human mesencephalic neural progenitor cell
Animal model/
Cell line
HBO
therapy
Method/
Duration
Neurogenesis Infarct
size
Neurobehavioral
testing
Mechanism Institute Reference
hmNPCs 100%,1.5
ATA
1 h/d × 5d
Ki67 ↑Mature neurons
(Tuji, NSE)
-GFAP
/ / HIF-a
Stabilizers
University of Leipzig,
Germany
Milosevic,
et al [7]
Table 5 effect of HBOT on other type of cells
Animal model/
Cell line
HBO
therapy
Method/
Duration
Proliferation Infarct
size
Neurobehavioral
testing
Mechanism Institute Reference
experimental
spinal cord
injury
Right
after
injury
100%,2.5
ATA
2h
D7 ↑GDNF(+)cell
↑VEGF(+)cell
↓TTC ↑BBB locomotor
scale
↓myeloperoxidase (MPO), tumor
necrosis factor-a (TNFa) and
interleukin-1b (IL-1b)
Taipei Medical
University
Tai, et al
[8]
Normal rats 60%, 1
ATA
3 days
Brdu
Single
injection
germinative
zone
↑Epithelial
Cells
/ / Oxidative stress? Washington
University
Shui et al
[9]
HMEC-1 100%, 2.4
ATA
1h
/ ↑HMEC-1
proliferation
/ / antioxidant, cytoprotective
genes upregulation
University of
Connecticut,
USA
Godman
et al [10]
Mu et al. Medical Gas Research 2011, 1:14
http://www.medicalgasresearch.com/content/1/1/14
Page 4 of 7paradigms, like 1.5 ATA for 60 minutes, HBOT will not
cause oxygen toxicity [34]. In a review of available treat-
ments for acquired brain injury (ABI), including TBI,
HBOT was suggested with strong level of evidence
among non-pharmacological interventions of ABI.
Furthermore, HBOT positively improved mortality with
level 1 evidence [35]. Laboratory experiments on HBOT
induced neurogenesis are needed to investigate the effi-
ciency of HBOT on TBI.
Autism
Autism is a neuro-developmental disorder associated
with hypoperfusion to several areas of the brain, defects
of neurogenesis and neuronal migration [36]. The first
multicenter, randomized, double-blind, controlled trial in
2009 found that 40-hour HBOT of 24% oxygen at 1.3
ATM produced significant improvement in children’s
overall functioning, receptive language, social interaction,
eye contact, and sensory/cognitive awareness compared
Figure 1 Potential mechanisms of HBOT and HIF-1a. In hypoxia, HIF-1a activates EPO and VEGF to promote neurogenesis. The accumulation
of HIF-1a further induces the expression of p53 protein and BNIP3, leading to cell death. HBOT stabilizes HIF-1a, preventing it from
overexpression and further, activates the Wnt pathway. Abbreviation: PHDs, prolyl hydroxylase; HIF-1a, hypoxia-inducible factor 1a; EPO, e
rythropoietin; VEGF, vascular endothelial growth factor; NGN1, Neurogenin1; TCF, T-cell factor.
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Another study in 2010 on 16 autism patients, adopting a
similar treatment paradigm, showed no effect on a wide
array of behavioral evaluations [38]. Basic research is
needed regarding neuroprotective effects of HBOT and
neurogenesis.
Special concerns
HBOT and malignancy
It has been previously suggested that neurogenesis
occurs within an angiogenic niche, where neurogenesis
is closely associated with vascular recruitment and sub-
sequent remodeling [39]. Therefore HBOT may also sti-
mulate angiogenesis by enhancing the proliferation of
fibroblasts, epithelial cells and blood vessels [40].
Concerns have been raised whether HBOT promotes
the proliferation of cancer cells. To date, there is little
evidence that HBOT causes malignant growth or metas-
tasis. A history of malignancy should therefore not be
considered as a contraindication for HBOT [40].
HBOT and oxidative stress
HBOT enhances the production of reactive oxygen spe-
cies (ROS) and causes oxidative stress in body tissues
[10]. Excessive accumulation of oxidative stress may
contribute to neurodegenerative processes and cell
death in the brain, as seen in diseases like Alzheimer’s
disease (AD) and Parkinson’s disease (PD) [41]. Since
HBOT-induced oxidative stress is directly proportional
to both exposure pressure and duration, the benefits of
HBOT, may outweigh the side effects due to the phe-
nomenon of hormesis. Hormesis is a process that results
in a functional improvement of cellular stress resistance,
survival, and longevity in response to sub-lethal levels of
stress. We suggest that this process might be beneficial
in the treatment of oxidative stress associated neurode-
generative diseases like AD and PD.
Conclusions and future directions
Abounding evidence has shown that HBOT promotes
neurogenesis. Future investigations need to be extended
to models of neurological diseases, including subarach-
noid hemorrhage (SAH), cerebral hemorrhage, AD, PD,
surgical brain injury (SBI) and autism for cell prolifera-
tion, survival and differentiation. Furthermore, studies
need to be conducted to explore whether HBOT
induced neurogenesis leads to a functional improvement
followed by large scale, strictly controlled clinical trials
Figure 2 Potential mechanisms of HBOT associated CREB activation and degradation: CREB activates its downstream genes when
phosphorylated, while PP1 catalyzes the dephosphorylation of CREB. PP1g is the core subunit of PP1. In hypoxia, PP1g is repressed, leading to
over-phosphorylation of CREB, followed by CREB ubiquitination and degradation by 26s proteasome. HBOT may reverse this process by
reactivating PP1g and blocking CREB degradation. Thus, phosphorylated CREB activates the downstream genes (BDNF, Bcl-2, VGF, et al.) to
promote neurogenesis. Abbreviation: PP1g, protein phosphatase-1; CREB, cAMP response element-binding; Ub, ubiquitin; CRE, cAMP response
elements; CBP, CREB binding protein.
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modality for neurological diseases.
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